Drug Profile
Research programme: antibacterials - Replidyne/Sequoia
Latest Information Update: 27 Apr 2007
Price :
$50
*
At a glance
- Originator Replidyne; Sequoia Sciences
- Class
- Mechanism of Action DNA synthesis inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Bacterial infections
Most Recent Events
- 10 Nov 2003 Preclinical trials in Bacterial infections in USA (unspecified route)